Immuno-oncology Drugs Market, by Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), by Disease Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate

Immuno-oncology Drugs Market, by Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), by Disease Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others (Breast Cancer, Thyroid Cancer, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. As immune system is a complex network of organs, cells and molecules that protect the body from foreign substances that cause infection. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

Market Dynamics

Increasing number of inorganic strategies such as product approval by the key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in December 2020, Blueprint Medicines Corporation, a biotech company, announced that they had received an approval from the U.S. Food and Drugs Administration for GAVRETO (pralsetinib) for the treatment of patients with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral precision therapy designed to potently and selectively target RET alterations that drive multiple tumor types.

Key features of the study:

• This report provides an in-depth analysis of the global immuno-oncology drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

• Global Immuno-oncology Drugs Market, By Treatment Type:
• Immune Checkpoint Inhibitors

PD-1

PD-L1

CTLA-4

• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others
• Global Immuno-oncology Drugs Market, By Disease Type:
• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Others (Breast Cancer, Thyroid Cancer, etc.)
• Global Immuno-oncology Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Immuno-oncology Drugs Market, By Region:
• North America

By Country

• U.S.
• Canada
• Latin America

By Country

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe

By Country

• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Country

• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East

By Country

• GCC
• Israel
• Rest of Middle East
• Africa

By Country

• South Africa
• Central Africa
• North Africa
• Company Profiles
• AbbVie Inc.*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

• AstraZeneca
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Ferring B.V.
• Enzo Biochem Inc.
• Celldex Therapeutics
• Atara Biotherapeutics, Inc.
• Apexigen
• BioNTech SE
• Blueprint Medicines Corporation
• Regeneron Pharmaceuticals Inc.
• CytomX Therapeutics, Inc.
• Agenus Inc.
• Betta Pharmaceuticals Co., Ltd.
• CStone Pharmaceuticals
• Amgen Inc.
• MediMergent, LLC,
• Gilead Sciences, Inc.
• ONKO-INNATE

“*” marked represents similar segmentation in other categories in the respective section.